Dutasteride and PP405 Interaction: Compatible | Peptide Database

Join others researching Meldonium — share findings, ask questions, and learn from real experiences Meldonium (marketed as Mildronate) is a cardioprotective and anti-ischemic drug developed at the Latvian Institute of Organic Synthesis in the 1970s by Ivars Kalvins. It is approved and widely prescribed in Latvia, Lithuania, Russia, and several other post-Soviet states for the treatment of coronary artery disease, heart failure, and cerebrovascular conditions. Meldonium has never been approved by the FDA or EMA, and it remains unavailable through conventional pharmaceutical channels in the United States and most of Western Europe. The drug gained worldwide notoriety in March 2016 when tennis star Maria Sharapova announced she had tested positive for meldonium after the World Anti-Doping Agency (WADA) added it to the Prohibited List effective January 1, 2016. Her positive test was far from isolated -- WADA reported that meldonium was the most common substance detected in doping control samples in early 2016, with hundreds of athletes across multiple sports testing positive, predominantly from Eastern European and Central Asian countries. This widespread use reflected meldonium's longstanding popularity among athletes in those regions, where it was both legally available by prescription and culturally accepted as a general-purpose cardioprotective and performance-enhancing agent. In the performance enhancement community, meldonium has attracted particular interest among anabolic steroid users seeking cardiac protection during cycles, given the well-documented cardiotoxic effects of supraphysiological androgen use including left ventricular hypertrophy, impaired diastolic function, and accelerated atherosclerosis. Meldonium exerts its primary pharmacological effect by inhibiting gamma-butyrobetaine hydroxylase (BBOX), the enzyme responsible for the final step in the biosynthesis of L-carnitine from gamma-butyrobetaine (GBB). By competitively blocking this enzyme, meldonium reduces endogenous carnitine production, which in turn lowers intracellular carnitine concentrations over time. Since carnitine is essential for the transport of long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system, reduced carnitine levels impair fatty acid beta-oxidation. This forces cells -- particularly cardiomyocytes and skeletal muscle cells -- to shift their metabolic fuel preference from fatty acid oxidation toward glucose oxidation. This metabolic shift is the cornerstone of meldonium's cardioprotective mechanism. Under ischemic conditions (reduced blood flow), fatty acid oxidation becomes metabolically inefficient and even harmful: incomplete fatty acid oxidation generates toxic intermediates (long-chain acylcarnitines and acyl-CoA species) that damage cell membranes and impair mitochondrial function. Glucose oxidation, by contrast, requires less oxygen per molecule of ATP produced and does not generate these toxic intermediates. By forcing the heart to rely more on glucose, meldonium effectively optimizes energy production under oxygen-limited conditions and reduces the accumulation of cardiotoxic lipid metabolites. Additionally, the accumulation of GBB that results from BBOX inhibition has been shown to stimulate nitric oxide (NO) production via an ester-mediated mechanism, promoting vasodilation, improving endothelial function, and reducing peripheral vascular resistance. Meldonium also upregulates the expression of glucose transporter proteins (GLUT-1 and GLUT-4) and activates components of the Akt-dependent cardioprotective signaling pathway, further enhancing myocardial resistance to ischemic injury.

Join others researching Sildenafil — share findings, ask questions, and learn from real experiences Sildenafil is the first PDE5 inhibitor to reach the market and remains one of the most widely recognized pharmaceuticals in the world. Originally developed by Pfizer scientists investigating treatments for angina and hypertension, sildenafil's pronounced effect on erectile function was discovered during Phase I clinical trials in 1992. It received FDA approval for erectile dysfunction in 1998 under the brand name Viagra, and subsequently gained a second FDA approval in 2005 as Revatio for the treatment of pulmonary arterial hypertension (PAH). Sildenafil is a shorter-acting PDE5 inhibitor with a half-life of 3-5 hours and a therapeutic window of approximately 4-6 hours. Unlike tadalafil, sildenafil absorption is significantly reduced by high-fat meals, and its lower selectivity for PDE5 over PDE6 (the retinal phosphodiesterase) can produce transient visual disturbances such as a blue-tinged color shift at higher doses. Despite the availability of longer-acting alternatives, sildenafil remains a first-line treatment for ED due to its well-established efficacy, extensive safety data spanning over 25 years, and wide generic availability. Sildenafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for the hydrolysis and degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. During sexual arousal, nitric oxide (NO) is released from nerve terminals and endothelial cells in the corpus cavernosum, activating soluble guanylate cyclase and increasing intracellular cGMP concentrations. Elevated cGMP activates protein kinase G (PKG), which phosphorylates multiple targets leading to smooth muscle relaxation, vasodilation of penile arteries, and engorgement of the corpora cavernosa with blood. By inhibiting PDE5, sildenafil prevents cGMP breakdown, prolonging and amplifying this vasodilatory cascade. Sildenafil requires sexual stimulation to be effective, as NO release is the initiating signal. In pulmonary arterial hypertension, the same PDE5 inhibition relaxes pulmonary vascular smooth muscle, reducing pulmonary artery pressure and pulmonary vascular resistance, thereby decreasing right ventricular afterload and improving exercise capacity. Sildenafil also has moderate inhibitory activity against PDE6, the phosphodiesterase isoform in retinal photoreceptors, which underlies the transient visual color changes reported by some users.